Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pralatrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 14/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 2/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 2/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TLR4 | O00206 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | GART | P22102 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pralatrexate SCHEMBL29904921 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL15075302 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL1890561 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL21633 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL2336143 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL29355142 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL29904925 | 1.00 | DHFR (1.00) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL17554355 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL17554353 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E | |
| Pralatrexate SCHEMBL28201941 | 0.99 | DHFR (0.98) | DHFRFOLR1SLC19A1SLC46A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531193-B1 | DIASTEREOMERS OF 10-PROPARGYL-10-DEAZAAMINOPTERIN FOR USE IN THE TREATMENT OF LUNG CANCER | ALLOS THERAPEUTICS INC (US) | 2016-07-20 | — | — | EP | claimed |
| US-9187481-B2 | (2S)-2-[[4-[(1R)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amin]pentanedioic acid for the treatment of inflammatory disorders | ALLOS THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | claimed |
| US-20140364437-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | ALLOS THERAPEUTICS, INC. | 2014-12-11 | — | — | US | claimed |
| US-8835433-B2 | Optically pure diastereomers of 10-Propargyl-10-deazaaminopterin and methods of using same for the treatment of cancer | ALLOS THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | claimed |
| US-20130197004-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same for the treatment of cancer | ALLOS THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | US | claimed |
| US-20110190305-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | ALLOS THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20240024326-A1 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2024-01-25 | — | — | US | disclosed |
| US-20240024326-A1 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2024-01-25 | — | — | US | disclosed |
| US-20210346294-A1 | GAMMA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-11-11 | — | — | US | disclosed |
| EP-2531193-B1 | DIASTEREOMERS OF 10-PROPARGYL-10-DEAZAAMINOPTERIN FOR USE IN THE TREATMENT OF LUNG CANCER | ALLOS THERAPEUTICS INC (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2794610-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING PRALATREXATE | PLUS CHEMICALS SA (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-9187481-B2 | (2S)-2-[[4-[(1R)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amin]pentanedioic acid for the treatment of inflammatory disorders | ALLOS THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187481-B2 | (2S)-2-[[4-[(1R)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amin]pentanedioic acid for the treatment of inflammatory disorders | ALLOS THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-8263354-B2 | Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2011096947-A1 | OPTICALLY PURE DIASTEREOMERS OF 10-PROPARGYL-10-DEAZAAMINOPTERIN AND METHODS OF USING SAME | ALLOS THERAPEUTICS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011096947-A1 | OPTICALLY PURE DIASTEREOMERS OF 10-PROPARGYL-10-DEAZAAMINOPTERIN AND METHODS OF USING SAME | ALLOS THERAPEUTICS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190305-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | ALLOS THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190305-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | ALLOS THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190305-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | ALLOS THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110111436-A1 | METHODS FOR ASSESSING CANCER FOR INCREASED SENSITIVITY TO 10-PROPARGYL-10-DEAZAAMINOPTERIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197004-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same for the treatment of cancer | DHPS, HCCS, SPR | DHFR 11/4885FOLR1 123/4885SLC19A1 848/4885 |
| US-20110190305-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | DHPS, C3AR1, HCCS | DHFR 22/4885FOLR1 166/4885SLC19A1 863/4885 |
| US-20140364437-A1 | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same | DHPS, C3AR1, HCCS | DHFR 22/4885FOLR1 166/4885SLC19A1 863/4885 |
| US-20240024326-A1 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | IFNG, FPGS, PML | DHFR 33/4885FOLR1 14/4885SLC19A1 133/4885 |
| US-20210346294-A1 | GAMMA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | IFNG, GMFG, IL2 | DHFR 30/4885FOLR1 20/4885SLC19A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.